Introduction
Neurological involvement in HIV is common. Overall, CT or MRI brain scanning provides additional information, and is often the most important tool in around 40-60% of patients with AIDS present with a neurological disorder at some stage,1,2 and this may determining the immediate management and the possibility of a lumbar puncture. However, making be the AIDS-defining diagnosis in 10-20% of HIV patients. 3 At post mortem, nervous system pathology an unequivocal diagnosis is often difficult without recourse to invasive procedures such as brain biopsy, is almost ubiquitous.1 While HIV encephalitis is probably the most common diffuse CNS disease, the and the approach adopted by this and many other centres is to make a provisional diagnosis (usually most common focal intracerebral pathologies are TE (50-70% of total intracerebral pathology), PCNSL TE) while awaiting the results of investigations or a response to treatment. While this is a practical (20-30%) and PML (10-20%). 4 Other pathologies such as tuberculomas or cryptococcomas are reported, approach, a firm diagnosis may remain elusive and may only be provided by a post-mortem examination. but are very rare in comparison. 5, 6 The above disorders would head a differential However, the outlook for patients with HIV and focal brain lesions other than TE is poor, and a diagnosis for all HIV patients presenting with intracerebral pathology pending further investigations.
balance needs to be struck between the need for an accurate diagnosis to enable advice and palliation Information such as CD4 lymphocyte count, toxoplasma serology and prophylactic drug regimen may to be given, and the need to avoid protracted and invasive investigation of dying patients. suggest one diagnosis above others in a given patient.
A lumbar puncture is possible in many patients patient survival. Selecting patients on diagnostic coding may miss patients with one of the above and polymerase chain reaction (PCR) amplification of viral DNA from a sample of CSF may be used to pathologies who were not coded correctly. However, as all of the above diseases have a rapidly progressive confirm a diagnosis. PCR techniques are available for the detection of DNA from many viruses, includnatural history, it is unlikely that any patient would have been missed completely, and the inclusion of ing Epstein-Barr virus (EBV) and JC virus ( JCV), the agents responsible for PCNSL and PML, respectthe CDC code for undefined neurological conditions was a further safeguard to ensure full acquisition of ively.7-11 Toxoplasma DNA can also be detected in CSF using PCR.12,13 While the sensitivity of some patients with focal intracerebral lesions. Also, patient records provided the prospective diagnoses, and the assays is disappointing, the specificity is uniformly high, and a positive result on PCR allows a confident information used to obtain each diagnosis, so that miscoding within the above categories could be diagnosis.
This study is a review of patients who presented corrected if necessary. Diagnosis date was defined as the admission date of the in-patient episode in with focal intracerebral lesions in 1994 and 1995 at a large London centre for the treatment of HIV. The which the diagnosis was made. The date of death was recorded in the notes of in-patients, and for presenting clinical features, supportive investigations, the response to treatment and survival are summarthose who died outside of the hospital, it was the date recorded by the community liaison team who ized. PCR techniques were in routine use throughout that time, and their contribution to the diagnostic were responsible for care of that patient. process is addressed. A pragmatic algorithm for the management of intracerebral lesions based on our experience is proposed.
Diagnostic definitions
Diagnoses were made prospectively by clinicians caring for each patient. Each diagnosis was initially
Methods
'presumed' until one of the diagnostic criteria (shown
Patient definitions
below) was met.
On presentation, patients were scanned using CT For this study, HIV infection was defined as written or MRI, and most patients had both forms of scanning documentation in the records of a positive result of either during the diagnostic period or as part of their an HIV test with appropriate CD4 lymphocyte subset clinical follow-up. Scans were reported prospectively results. AIDS or AIDS-related refers to the subgroup by radiologists with experience in HIV neuroradiolof patients with HIV infection who met the Centers ogy who were aware of the clinical picture at the for Disease Control (CDC) diagnostic criteria for time of presentation. The radiological criteria for the AIDS (in the UK this does not include a CD4 count diagnosis of intracerebral pathology in HIV patients <200/mm3).
have evolved in the course of the epidemic, are well established, and have recently been reviewed.14 A
Patient ascertainment
detailed review of the criteria for each diagnosis is beyond the scope of this paper, although 'typical' From January 1994 to January 1996, there were 95 patients with focal intracerebral pathology who radiological appearances of TE would include multiple (>5) lesions with ring contrast enhancement, attended the Chelsea and Westminster Hospital Kobler Clinic. Since 1993, a computerized summary surrounding oedema and mass effect, with basal ganglia and grey/while matter borders as common of HIV-patient activity has been maintained, with all diagnoses on each patient coded by CDC category.
sites for TE abscesses. On imaging, PCNSL may present with fewer lesions, and may have a more This coding database is part of a system which provides routine laboratory results, so all patients homogenous pattern of contrast enhancement. Extension of a lesion across the corpus callosum or who have ever had an investigation in the HIV/GUM department are included. New diagnoses are coded periventricular placement with subependymal spread suggests PCNSL rather than TE. Radiology alone is on a weekly basis, on review of all in-patient records.
Patients with CDC diagnostic codes for presumptnot specific enough to differentiate TE from PCNSL in every patient at presentation, although this distincive or confirmed TE (4C1: 38, 4C1: 16, respectively), PCNSL (4D: 56, 4D: 50), PML (4C1: 29) or 'neurologtion becomes easier in retrospect after a period of specific antitoxoplasma treatment, as a radiological ical other' (4E: 109) were identified, and all available medical records and images were reviewed. Data response is an accepted CDC definition of TE.15 Typically, areas of PML appear on MRI as high signal were abstracted on demographics, medical history, risk factors for HIV, initial presentation for each of on T 2 -weighted images with corresponding hypointensity on T 1 weighting. The lesions are in the white the diagnostic categories, duration of treatment and matter, rarely have contrast enhancement and have
Statistical analysis
no mass effect.
Descriptive statistics were used to calculate means. A confirmed diagnosis was one which met the Estimations of statistical significance were made following diagnostic criteria after appropriate investiusing the computer-based SPSS statistical package. gations or a trial of treatment (TE). The remaining patients had a presumed diagnosis. 
TE

Results
Radiological
Other diagnoses
Patient risk factors
In addition to the above, other diagnoses were: one CNS secondary spread of systemic lymphoma, one All of the patients were white male homosexuals infarct and one patient with atrophy following intraexcept for one female intravenous drug user. All cerebral trauma. Patients for whom there was inadwere Caucasians except for one male of Afroequate information to allocate them to one of the Caribbean origin. above groups fell into the 'undetermined' category.
Viral PCR techniques
Age, CD4 count at diagnosis and survival after diagnosis
All CSF samples for viral PCR, including JCV and EBV were sent from this centre to University College Table 1 shows the mean age of each patient at Hospital where viral PCR was performed according diagnosis, the mean CD4 count at diagnosis (most to methods detailed elsewhere.11,16 recent count) and the median survival in days following the diagnosis. In the PML group, there was
Toxoplasma titres
one patient who had a splenectomy some time before the diagnosis of PML, and had elevated CD4 Blood for toxoplasma titres was routinely taken from counts. The mean CD4 count excluding this patient all patients, usually at their initial presentation at this was 116/mm3. There was no significant difference centre, and again once CD4 count fell to around between the CD4 count in any of the patient groups. 200/mm3. Thereafter, the titre was rechecked every There was no significant difference between the year or so. If a titre was 1516 or above on screening ages of the patients in any of the diagnostic groups, with an Eiken toxoplasma reagent test ( Japan), a with an overall mean age of 38 years. further sample was sent to the toxoplasma reference Figure 1 shows Kaplan-Meier survival plots for the confirmed diagnostic categories (1a) and for TE and quone or azithromycin at the time of diagnosis of new intracerebral pathology.
presumed TE (1b). patients. Median toxoplasma titres were <1516 in
all diagnostic groups, except the TE group, where it Toxoplasma titres <1516 were considered 'negative' was 15256 ( p=0.001, one-way ANOVA). by our laboratory and not further quantified. The number of patients with toxoplasma titres >1516 Toxoplasma prophylaxis and maintenance in each group is shown in Table 1 . Eighteen of the treatment 20 TE patients (90%) had elevated titres, compared to five of the 12 presumed TE patients, three of the Of the 20 patients with definite TE, 17 were first episodes of TE, and three were relapses of TE which confirmed PCNSL patients and one of the PML had responded to earlier treatment. Mean survival in seizures and corresponding focal neurological deficits, whereas the other three had generalized seizures the relapsed group was 515 days, which is not significantly different from the overall mean survival with no signs of focal neurology. One patient was known to be epileptic before his HIV diagnosis. of 476 days in the TE group. Seven patients (41%) with a first episode of TE were on some form of Of the TE patients, one presented with focal seizures and signs, while the other two had generalprimary antitoxoplasma prophylaxis. Table 1 shows the number of patients taking prophylaxis against TE; ized tonic-clonic seizures and no focal neurology. In the remaining diagnostic groups, both of the in the majority of cases in each group the drug was cotrimoxazole, taken primarily as PCP prophylaxis.
presumed PCNSL patients had focal seizures and focal signs, and in the presumed PML and presumed TE prophylaxis was significantly more likely in the PCNSL group (88%) compared to those with a first TE groups, there was one patient each with focal fitting and focal signs and one with generalized diagnosis of TE (43%, p<0.002, x2 test).
seizures without focal signs.
All patients who presented with seizures had a
CSF values
CT brain scan, which showed focal abnormalities Table 2 shows the protein, glucose and white cell regardless of seizure type. counts in the CSF in those patients who had a Headache occurred in between 8% and 38% of lumbar puncture at the time of diagnosis. The values patients, and cognitive dysfunction was present in in PML patients are within normal limits, and with 7% of the TE group, 29% of the PML group and in only a mild elevation of protein in the TE and 63% of the PCNSL group, where it was the most presumed PML groups. CSF in PCNSL patients occacommon presenting feature. sionally showed a lymphocytic pleocytosis, and tended towards raised protein, but this was not universal. Few lumbar punctures were performed in Discussion patients with a diagnosis of TE.
Between 2% and 2.5% of the HIV population attending this centre in 1994 and 1995 had a new
Clinical features
diagnosis of focal intracerebral pathology. The majority had TE responsive to treatment (21%), with Table 3 shows the number of patients in each group who presented with focal signs. All seven PML confirmed diagnoses of PML and PCNSL in 7% and 8%, respectively. It is difficult to make direct comparpatients presented with focal deficits, but focal presentation occurred in only 60% of the PCNSL patients isons between these figures and those of other studies, as the reference populations are different. and 59% of the TE patients, despite sometimes extensive intracerebral lesions. The most common However, it is interesting to compare them to those obtained in a retrospective study of 122 patients focal signs in each diagnostic group were: (i) diplopia and hemi-or quadrantanopia in the PCNSL group;
with AIDS treated at this centre until their death in 1987.18 Of these, 64 were investigated for neurolog-(ii) motor weakness, especially hemi-or monoparesis or limb incoordination, and aphasia or other speech ical disease and 15 had focal neuropathology, which was confirmed as TE in 33%, PCNSL in 20% and deficit in the PML group; and (iii) incoordination, either of limbs or gait ataxia, in the TE group. PML in 7%. Overall, patients with focal neurological disease formed 25% of those with a neurological Seizures occurred in between 12 and 50% of patients at presentation in all categories except PML, complaint. This study highlights the difficulties in making a where no patients presented with seizures but two had seizures at some point during the course of their confirmed diagnosis in HIV patients with focal intracerebral lesions in clinical practice. Only 35 of the illness. In the PCNSL group, one patient had focal 95 patients had a firm diagnosis based on strict alive at September 1996), significantly longer than in any other diagnostic group including those with diagnostic criteria. However, for practical management of HIV patients with intracerebral lesions, a presumed TE who had a mean survival of 168 days (median 33 days, see Figure 1 , a and b). definitive diagnosis may not be important, because median survival was very poor for all patients who
The survival of patients who responded to TE treatment at this centre compares favourably with a failed a trial of anti-toxoplasma therapy. We propose a management algorithm (Figure 2 ) for mass lesions study of 115 patients with TE between the years 1981 and 1990 in San Francisco, where mean in HIV patients. It has been kept simple for clarity, and is not intended to be exhaustive. Areas of survival after a first episode of TE was 265±212 days, among the 96 patients (83%) who responded controversy, or where additional complexity has been left out, will be discussed below. The main to treatment.19 Median survival of 5 months was seen in a more recent study of patients from 1990 diagnostic difficulties arise in trying to distinguish between TE and PCNSL at presentation, and much to 1995 in Atlanta.20 Also, survival was longer in this present study than in an earlier study at this of this discussion will address this problem. In the algorithm (Figure 2 ), all patients are started on anticentre in 1988 when survival was a median of 4 months.18 Longer survival was reported in a cohort toxoplasma treatment; but in those in whom TE is less likely at the outset, further investigations are of 25 patients maintained on full treatment doses of pyrimethamine and either sulphadiazine or clindastarted immediately rather than waiting for clinical or radiological deterioration to occur. mycin for at least 503 days without relapse.15 However, there is a high rate of drug toxicity with The other main diagnosis, PML, produces lesions with characteristic appearances on MRI scanning TE treatment,17 and most centres reduce drugs to maintenance doses after 6 weeks at higher levels. which should not cause confusion with the other groups of patients (unless there is multiple pathoTreatment at this centre was usually sulphadiazine and pyrimethamine as first choice, with clindamycin logy-see later). Other pathologies such as tuberculomas, cryptococcomas, and intracerebral atypical substituted for the sulphadiazine in the event of intolerance. Atovaquone was used in those who mycobacteria are very rare in comparison to TE and PCNSL (none were seen over 2 years at this centre) became intolerant of the above drugs. There were frequent changes of both drugs and doses during the and are almost always associated with systemic features of the underlying disease, allowing a diatreatment period, so it is not possible to draw any conclusions about the relative efficacy of any particugnosis to be made. lar regimen from this study.
Patients with TE Partial or late responders to TE treatment
Patients who met the CDC diagnostic definition of TE of a response to specific treatment in the presence Around 80% of patients with TE will respond to one or other of the main drug regimens,19,21,22 but TE of typical radiology15 had a good outcome compared to other patient groups. Survival was a mean of 476 may take up to 6 weeks to respond to treatment, although in the majority (95%) this occurs within 2 days (median 446 days, including seven patients still weeks,19 and many patients show a response within limb incoordination, while relatively few patients presented with a focal motor deficit. A high frequency a few days.22 Patients with a prompt response to of gait and co-ordination problems has been noted treatment identify themselves readily. Those who in other studies,19 but this was usually in combination show an equivocal response to initial therapy present with focal motor signs such as hemiparesis,18,24 and more of a diagnostic problem. The question is most patients presented with focal deficits which whether these patients have TE, which may be corresponded to the sites of intracerebral lesions.1 partially responsive to therapy, in which case a more Choreoathetosis has been reported as being pathoprolonged or different anti-toxoplasma regimen may gnomonic for TE,1 but was not seen in any of our be tried, or whether they actually have PCNSL.
patients. Overall, focal deficits have been found in Recognizing these patients is important because 70-80% of patients with TE in other studies.2,5,19,24 the survival of patients with slowly-responding TE Variable frequencies of non-localizing signs such as may be prolonged; 54 weeks in a study of biopsycognitive dysfunction (6%), headache (29%) and proven TE in patients with a slow initial response. 23 seizures (18%) were noted in this study. These were In the management algorithm (Figure 2 ), a partial also at a low frequency compared to other studies response at 2 weeks may lead to a further scan after where confusion has been be noted in more than a more prolonged period of treatment, the addition 60% of patients.1,2,19 or substitution of anti-toxoplasma drugs, or may
In patients with PCNSL, cognitive dysfunction was prompt further investigations (route not shown).
the most common presenting feature (63%). Although focal motor deficits were less prominent, they still
Clinical features
occurred in 60% of patients, which is a similar Clinical features at presentation were not discriminatfinding to that in other studies.2 None of the clinical ory (Table 3 ). In those with TE, the overall rate of features was specific for either TE or PCNSL, and as HIV patients often presented with surprisingly few focal presentation was 59%, usually with signs of signs despite extensive intracerebral pathology, the and negative predictive values of 90-100% and threshold for brain scanning is low at this centre.
97-99%, respectively.30,32 However, there have been This may account for the discrepancy between this reports of the detection of EBV by PCR in the CSF study and others in the detection of patients with in the absence of visible lesions on scanning. These brain lesions before signs of focal deficit were have been interpreted as being due to microscopic apparent. Also, if this represents early detection, it foci of lymphoma, or alternatively as being caused may also partly account for the prolonged survival by contamination of the CSF sample by EBV in of our patients with TE compared to that seen in lymphocytes from the peripheral circulation.32 This some other studies. Furthermore, this reaffirms the study did not include patients without lesions on value of brain scanning early in the investigation of brain scanning, but caution is still needed, as the symptomatic HIV patients.
visible lesions may not be caused by PCNSL. Multiple pathology is common in HIV patients, with estimates ranging from 13.5% in a series of 1286 patients, to
Lumbar puncture and routine CSF 29% in a series of 69 patients, all of whom had investigation histological confirmation of the various diseases.33 Lumbar puncture is a minimally invasive procedure, Also, the development of PCNSL in patients who but is often not possible in patients with intracerebral have been successfully treated for TE is well recogmass lesions (e.g. it was performed in less that half nized. Usually, the rapid progression of PCNSL will of a series of 136 patients with focal brain lesions provide swift clarification as these lesions expand, evaluated using PCR and histology)13. When perwhile those around them may shrink in response to formed, the main reason was to obtain a sample of anti-toxoplasma treatment. Serial CT or MRI scans CSF for PCR analysis. This is because there are are needed throughout treatment. A single scan is abnormalities on routine investigations of CSF in HIV not sufficient for a definitive diagnosis, as has been patients throughout their illness, which makes it a established by several studies.27,34-37 In the proposed poor tool for identifying patients with secondary management algorithm (Figure 2 ), a positive PCR for infection without specialized tests. Even a sample EBV is used as confirmation of a diagnosis of PCNSL with all results in the normal range cannot rule out and may obviate the need for further investigation. serious infection, as can be seen from the results of However, it must be emphasized that each diagnosis this study in patients with PML in particular ( Table 2) .
is based upon several complementary findings. In one study, 63% of CSF results were abnormal, During this study, by the time that a confirmatory although 80% of the study population were asympto-PCR was available, each patient with PCNSL had matic with CD4 counts above 400/mm3. 25 In a not shown benefit from a period of anti-toxoplasma review of several studies, a pattern of abnormalities treatment and showed progression of their lesions was described which varied with progression of HIV on repeat brain scanning. infection; the CSF pleocytosis commonly found in Further investigations including thallium scanning the early phase of HIV infection fell with time, while or brain biopsy (see later) may be considered in CSF protein rose. On the basis of those results, the some patients in whom lumbar puncture may not be author suggested that a secondary infection besides possible, or who have a lesion at a suitable site HIV need only be considered if a pleocytosis of for biopsy. >100/mm3 was found.26 That conclusion may have PCR techniques are available for the detection of reflected the lack of investigations such as PCR toxoplasma DNA in the CSF, but the problem of available at the time of publication, and our more multiple pathology is further confounded by the low recent experience would suggest that in late HIV sensitivity of the test-generally around 50-60% in infection, a pleocytosis of >10 white cells is often large studies-although specificity approaches significant. There may be a lymphocyte pleocytosis 100%.12,38 Treatment of TE also rapidly reduces the in patients with PCNSL, but even then it is rare for sensitivity of PCR.12 CSF cytology to confirm the diagnosis of PCNSL, 27 As a result, toxoplasma PCR is not in routine use although it may have a higher diagnostic yield in at this centre and is limited to the testing of stored patients with CNS spread of systemic lymphoma28 samples taken before therapy in those patients who (it was diagnostic in the one patient with systemic have failed 2 weeks of anti-toxoplasma treatment, lymphoma in this study).
who were safe to lumbar puncture, and who had a negative EBV PCR. In these few patients, a positive
PCR techniques
toxoplasma PCR would strengthen the resolve to continue with anti-toxoplasma treatment, but a negaThe sensitivity of PCR for EBV (which is always tive result may not alter management, due to the associated with PCNSL)7,29 is around 50-100%, with a specificity of 94-100%. [30] [31] [32] [33] This produces positive poor sensitivity of the test.
small, several reports have shown a sensitivity and Brain biopsy specificity of between 80-100%, comparing thallium Brain biopsy was diagnostic in one patient with PML scan results with those of brain biopsy or postand two pre-mortem diagnoses of PCNSL were mortem examinations.44,45 In our recent experience confirmed at post-mortem examination. While histoof five patients who underwent a thallium scan, two logical examination is considered the gold standard were 'positive' for PCNSL, one of whom was also for diagnosis, 4-36% of biopsies are non-EBV-PCR-positive in a sample of CSF. The other had diagnostic,39-41 and brain biopsy is perceived as a posterior fossa mass which prevented lumbar highly invasive. It has a morbidity of up to 12% and puncture. Both patients deteriorated rapidly. Of the mortality of 2%, which is higher than in the nonthree who were thallium scan 'negative' for PCNSL, HIV population and largely made up of excess two were also EBV-PCR-negative, and both eventuhaemorrhagic complications.39,42 Most importantly, ally made a good response to a prolonged trial of biopsy confirmation of a diagnosis has not been anti-toxoplasma therapy. The remaining patient was shown to improve the survival of HIV patients, positive for EBV on CSF PCR, and initially responded except when performed as an early procedure before to antitoxoplasma treatment with radiological resoa trial of empirical anti-toxoplasma treatment in lution of his lesions, but within a month he deteriorselected patients. This is largely because treatment ated clinically and further brain scanning revealed a is ineffective for most HIV-related intracerebral new periventricular lesion radiologically typical of lesions. The survival advantage of early biopsy was PCNSL. This last lesion was below the resolution of an estimated 31 days in one decision-analysis study, both MRI and thallium scanning at presentation. An which the authors admitted was a poor return for early biopsy in this latter patient may have provided the increased risk involved in the test.40 Additionally, false reassurance. the possibility of multiple pathology increases the probability that a single biopsy may not identify the Toxoplasma serology most important pathology. It has been suggested that a biopsy should be considered on the appearance
The diagnostic value of toxoplasma titres has been of each new pathology,33 but this is untenable in a source of much debate. Eighteen of the 20 patients our patient group.
with TE had serum toxoplasma titres >1516, showIn a departure from some earlier management ing past infection with toxoplasmosis and risk of schemes, brain biopsy is not included in our algoreactivation. The TE group had proportionately more rithm (Figure 2) . A combination of clinical and seropatients with elevated titres than any other group, logical findings, serial scans, CSF PCR or thallium and the median titre was also higher at 15256, scan results (see below) and a response to a trial of compared to 1516 for all other groups. The rate of anti-toxoplasma treatment, should remove the need positive toxoplasma serology in a population varies for this investigation in the majority of patients. The geographically, and its value in discriminating emphasis of our algorithm is to optimize survival, between TE and other CNS lesions diminishes with rather than to make a diagnosis. While treatment for increasing prevalence. Even so, in a study from PCNSL remains ineffective, the hope of prolonged France, where 60-80% of HIV patients have serolosurvival in HIV patients with intracerebral disease gical evidence of toxoplasma exposure, antilies in a response to anti-toxoplasma therapy.
toxoplasma antibodies were more frequently seen in Provided that every effort is made to ensure that an those with TE than those without it (87% vs 71%, adequate trial of these drugs is given, it is unlikely p<0.001).46 A recent study estimated the rate of that survival would be improved by a tissue diapositive serology in a mixed population of HIV gnosis.
patients in South London to be 23%.47 Using this figure, the only diagnostic groups with more than the expected number of patients with positive sero- studies assert that TE is very unlikely in patients with value of prophylaxis in preventing TE in those with evidence of previous exposure to toxoplasmosis, and low titres (<1516) or negative toxoplasma serology,17,27,48,55-57 although this assertion may be biased in areas where the prevalence of antitoxoplasma antibodies is high, a prophylaxis history is the most by studies which exclude patients with negative toxoplasma serology. Studies have documented TE important discriminator in determining who has TE rather than PCNSL.46 in patients with low toxoplasma titres,24 however, and one reported 'negative' toxoplasma serology (<1516) in 22% of 18 patients with biopsy-proven PML TE,19 and the French study noted above found that 3/24 (12.5%) patients with TE were antibody-PML produces lesions that appear on MRI brain scans as areas of white matter/high signal on negative.46 In the present study, 10% of the patients with TE had a blood titre <1516.
T2-weighted images with corresponding areas of low signal on T1-weighted images. Gadolinium enhanceTitres below 1516 may be significant in the context of advanced immunosuppression. 24 We have ment may occur in around 10% of lesions, but there is no mass effect. These scan appearances are seen positive toxoplasma serology become 'negative' in patients with advanced HIV and remain so despite sufficient, in the absence of confounding multiple pathology, to avoid confusion with the previous an episode of fully-responsive TE. The two titrenegative patients in this study survived for 610 and diagnoses. At presentation, focal signs were universal in the 153 days from diagnosis. The first patient died of an unrelated opportunistic infection, and the patient confirmed PML group, with limb incoordination or hemiparesis predominating. Focal neurological defiwith the shorter survival was left with significant neurological deficit despite complete radiological cit corresponding to the sites maximal involvement on brain imaging was the usual presentation of PML resolution of the TE lesions, and elected to discontinue all treatment one month before his death.
in many other studies.59-63 Weakness, visual deficits and cognitive abnormalities are reported in one third A positive toxoplasma titre remains a strong predictor of TE as the final diagnosis in the UK. In one of patients and motor weakness of some sort is present in up to 80% at diagnosis.59 Although they decision analysis study, it was calculated that positive toxoplasma serology (>1564) and ring-enhancing are commonly seen in patients with PML,59,61 none of the patients in this study had seizures at presentalesions on CT was 81% predictive of TE.58 A more recent prospective study of 136 consecutive HIV tion, but two developed seizures during the course of their illness. patients with focal brain lesions used Bayesian analysis to produce a probability of TE of 0.87 in patients Confirmation of the diagnosis of PML relied upon detection of JCV DNA in the CSF of patients with with positive toxoplasma serology and who were not taking prophylaxis (the probability reduced to 0.78 lesions typical of PML on brain scanning. The detection limit of most PCR techniques for JCV DNA for those on prophylaxis). In those who were toxoplasma-seronegative, the probability of TE was 0.22 is in the order of 10-100 viral genomes,11,30,64,65 but CSF concentration of free DNA is thought to be (0.06 if TE prophylaxis was taken) while the probability of PCNSL was 0.74 (rising to 0.96 if EBV DNA low32 because JCV is largely intracellular and found deep in white matter. Accordingly, test sensitivities was detected in a sample of CSF).42 The authors used these probability figures to recommend a course of around 75-80%11,65 have been reported (and may be lower in routine clinical practice), although speciof investigations, i.e. no lumbar puncture in toxoplasma-seronegative patients on TE prophylaxis, ficity is better at 92-100%.11,30,65 With a false negative rate of 20-30%, JCV PCR on CSF is only even though a positive toxoplasma PCR in this group would increase the probability that they had TE to useful if positive. Patients with a negative result may be retested as the disease progresses, which has 0.96. However, survival figures were not given for the various diagnostic groups. In this study, the been shown to increase sensitivity,30 undergo a brain biopsy, or accept an unconfirmed diagnosis. Other difference between the survival in the TE and PCNSL groups is so great that a 6% chance of a diagnosis studies have found that in patients with focal brain lesions without mass effect, PML remained the most of TE is important, and may warrant an investigation such as toxoplasma PCR, even if the expected yield likely diagnosis whether or not a CSF sample was positive for JCV on PCR.42 Although JCV PCR may was low.
be more likely to be positive later in the course of the disease, studies have failed to show correlation
Toxoplasma prophylaxis
between the radiological extent of PML lesions and the likelihood of a positive PCR. There was a trend In this study, 43% of those with TE were taking prophylaxis compared to 88% of those with PCNSL towards longer survival in the presumed PML (negative JCV PCR) group: median 75 days vs. 30 
